| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Medical and professional news |
| Population | Men |
| Source | Urology Times |
| URL | urologytimes.com/view/hhs-requests-testosterone-therapy-label-updates-citing-new-safety-data (opens in a new tab) |
Specific Claim Evaluated
The requested label changes rest mainly on TRAVERSE, which found transdermal testosterone noninferior to placebo for major adverse cardiovascular events, at 7.0% versus 7.3%.
Primary Research Supporting or Contradicting the Claim
In TRAVERSE, the primary cardiovascular end point occurred in 7.0% of the testosterone group and 7.3% of the placebo group, meeting noninferiority (Lincoff et al., 2023). The FDA requested label updates in June 2026 (U.S. Food and Drug Administration, 2026b).
Corrected Evidence-Based Interpretation
The report is correct.
Rationale for Grade
The article states that the changes are proposed, reports the trial figures accurately and notes continued recommendations for prostate monitoring.
References
- Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events" - U.S. Food and Drug Administration. Testosterone information. Postmarket drug safety information for patients and providers. Updated June 2026.
Supporting excerpt: "FDA requested updates to testosterone prescribing information in June 2026"